Breaking News

AstraZeneca Buys Amgen’s Biologics Bulk Mfg. Facility

Expands biologics manufacturing capability in the U.S. to support advancing pipeline

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

AstraZeneca has purchased a high-tech biologics bulk manufacturing facility from Amgen, expanding its biologics manufacturing capability in the U.S. The LakeCentre facility, located in Boulder, CO will increase production capacity to support its portfolio of biologics.   The company will begin staffing the facility to support infrastructure improvements, and it is expected to be operational and licensed for commercial production by late 2017.   Down the road, this site could create as many a...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters